Dupilumab Improves Histologic and Endoscopic Outcomes in Children Aged 1 to <<12 Years with Eosinophilic Esophagitis (eoe): 52-Week Results from the Phase 3 EoE KIDS Trial

Journal of Allergy and Clinical Immunology（2024）

Cited 0|Views32

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined

Dupilumab Improves Histologic and Endoscopic Outcomes in Children Aged 1 to &lt;<12 Years with Eosinophilic Esophagitis (eoe): 52-Week Results from the Phase 3 EoE KIDS Trial